Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAO: Otamixaban vs UFH + Eptifibatide in NSTE-ACS
NCT01076764Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2010
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 55
01
Overview
A Phase 3 trial of otamixaban in acute coronary syndrome (ACS), sponsored by Sanofi. Started Apr 2010; status: completed.
02
Drugs
otamixaban
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT01076764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01076764.